Cargando…
Rectal cancer sub-clones respond differentially to neoadjuvant therapy()
Treatment of locally advanced rectal cancer includes chemotherapy, radiation, and surgery but patient responses to neoadjuvant treatment are variable. We have shown that rectal tumors are comprised of multiple genetically distinct sub-clones. Unique sub-clones within tumors may harbor mutations whic...
Autores principales: | Frydrych, Lynn M, Ulintz, Peter, Bankhead, Armand, Sifuentes, Christopher, Greenson, Joel, Maguire, Lillias, Irwin, Regina, Fearon, Eric R., Hardiman, Karin M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745489/ https://www.ncbi.nlm.nih.gov/pubmed/31521947 http://dx.doi.org/10.1016/j.neo.2019.08.004 |
Ejemplares similares
-
Intra-tumor Genetic Heterogeneity in Rectal Cancer
por: Hardiman, Karin M., et al.
Publicado: (2015) -
Rapamycin Inhibition of Polyposis and Progression to Dysplasia in a Mouse Model
por: Hardiman, Karin M., et al.
Publicado: (2014) -
Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer()()
por: Smithson, Mary, et al.
Publicado: (2022) -
Clinical and pathological outcomes of induction chemotherapy before neoadjuvant radiotherapy in locally‐advanced rectal cancer
por: Hardiman, Karin M., et al.
Publicado: (2019) -
Beneficiaries of radical surgery among clinical complete responders to neoadjuvant chemoradiotherapy in rectal cancer
por: Zhang, Shu, et al.
Publicado: (2021)